相关实验视频
Updated: Jul 23, 2026

16:11
Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
35.1K
在使用左心室辅助装置后缓解术后右心室功能障碍:RV保护研究.
Anthony J Kanelidis1, Leo Gozdecki1, Mark N Belkin1
1Department of Medicine, Section of Cardiology, Advanced Heart Failure and Transplant Cardiology, University of Chicago Medical Center, Chicago, IL.
Journal of cardiac failure
|February 15, 2025
概括
在左心室辅助装置 (LVAD) 植入后,保护右心室 (RV) 的新策略显著提高了存活率,减少了与血液动力学相关的不良事件 (HDREs) 和与血液相容性相关的不良事件 (HRAEs). 这种方法为LVAD患者提供了更好的结果.
科学领域:
- 心血管外科心血管外科
- 机械循环支持 机械循环支持
- 心脏衰竭管理的管理
背景情况:
- 左心室辅助装置 (LVAD) 改善了结果,但与血液动力学相关的不良事件 (HDREs),如右心室衰竭 (RVF),持续存在.
- 虽然HeartMate 3 LVAD已经改善了血红相容性,但高强度抗体仍然是一个重大挑战.
- 在LVAD后调查减轻RVF和其他HDREs的策略至关重要.
研究的目的:
- 评估一个全面的,预先的RV保护策略,以减少LVAD植入后的RVF和其他HDREs.
- 为了比较这种新型RV保护策略与常规护理的有效性.
- 评估对没有HDREs和HRAEs的生存率的影响.
主要方法:
- 预期随机试验,将VR保护策略与LVAD患者的通常护理进行比较.
- RV保护策略涉及血液动力学,呼吸系统和药物优化,针对RV后负载,预负载, perfusion,收缩性,速率/节奏和几何.
- 主要结局:在24周内没有HDREs或HRAEs的生存率;次要结局:严重的RVF.
主要成果:
- 在RV保护策略组显示,在24周内,没有HDREs或HRAEs的生存率显著更高 (80%对40%,P=0.04).
- 在RV保护策略组中没有出现HDREs,而在常规护理组中这一比例为30% (P=0.067).
- 在RV保护策略组中没有观察到严重的RVF,而在常规护理组中为30% (P=0.20).
结论:
- 一个全面的,预先的RV保护策略显著提高了LVAD植入后免于HDREs和HRAEs的生存率.
- 这一策略有效地减轻了RVF和其他HDREs的风险.
- 这些发现支持在LVAD管理中采用这种主动VR保护协议.
相关概念视频
Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...

